TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23453789

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZRS)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 225
Study: 21467949

Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.1 mmol/kg BW
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.2 mmol/kg BW
Number of subjects: 175

Group type: COMPARATOR
Intervention: Gadoteridol 0.2 mmol/kg BW
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Gadobutrol and Gadoteridol
Number of subjects: 175
Study: 19115651

Group type: EXPERIMENTAL
Intervention: Bicarbonate-balanced fluid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plasma-Lyte 148
Number of subjects: 20
Study: 17052475

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (Herbst appliance)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 215
Study: 14600927

Group type: EXPERIMENTAL
Intervention: Adenosine (140 micro g/kg/min) with low level exercise protocol (300 MBq and 700 MBq Tc‐99m tetrofosmin for stress and rest respectively)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Treadmill exercise (700 MBq Tc‐99m MIBI)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 26
Study: 10573515

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13‐15 mg/kg daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9051516

Group type: EXPERIMENTAL
Intervention: Polyimide haptics
Number of subjects: 121

Group type: COMPARATOR
Intervention: Polypropylene (PP) haptics
Number of subjects: 121
Study: 2070529

Group type: EXPERIMENTAL
Intervention: Gentamicin with hydrocortisone ear‐drops
Number of subjects: 64

Group type: COMPARATOR
Intervention: Betamethasone ear‐drops
Number of subjects: 64
Study: 6859584

Group type: EXPERIMENTAL
Intervention: 2 mg morphine epidurally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 mg morphine epidurally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 mg morphine epidurally
Number of subjects: 20
Study: 31349042

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant radiation therapy (S+ART)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Surgical monotherapy (SM)
Number of subjects: 62
Study: 31119692

Group type: EXPERIMENTAL
Intervention: Esaxerenone (5 mg) administered in the fasting state as a single oral dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Esaxerenone (5 mg) administered in the postprandial state as a single oral dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fasting intravenous administration of esaxerenone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of fasting versus postprandial oral administration of esaxerenone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Overall safety assessment
Number of subjects: 24
Study: 28130796

Group type: EXPERIMENTAL
Intervention: Menu labeling (calorie information provided)
Number of subjects: 716

Group type: COMPARATOR
Intervention: No menu labeling (calorie information not provided)
Number of subjects: 716
Study: 25491433

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day
Number of subjects: 1987

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg/day
Number of subjects: 1987
Study: 23317717

Group type: EXPERIMENTAL
Intervention: Laminar flow theatre environment
Number of subjects: 170

Group type: COMPARATOR
Intervention: Non-laminar flow theatre environment
Number of subjects: 170
Study: 20643699

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (n=12)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 20
Study: 20635756

Group type: EXPERIMENTAL
Intervention: TNK-tPA (tenecteplase)
Number of subjects: 0
Study: 16754836

Group type: EXPERIMENTAL
Intervention: DMXB-A (lower dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DMXB-A
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15086665

Group type: EXPERIMENTAL
Intervention: Increased Velocity Exercise Specific to Task (InVEST), n=11
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control exercise group (n=10)
Number of subjects: 21
Study: 12297781

Group type: EXPERIMENTAL
Intervention: Electronic radial array echoendoscope
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mechanical radial echoendoscope
Number of subjects: 14
Study: 10203647

Group type: EXPERIMENTAL
Intervention: Monitored group (home uterine activity monitoring)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (unmonitored)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Monitored group
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study: 7583611

Group type: EXPERIMENTAL
Intervention: Room air (group I)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 80% oxygen (group II)
Number of subjects: 70
Study: 2178941

Group type: EXPERIMENTAL
Intervention: Parenteral estrogen (polyestradiol phosphate 80 or 160 mg i.m. monthly)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bilateral subcapsular orchiectomy
Number of subjects: 11
Study: 760745

Group type: EXPERIMENTAL
Intervention: Biperidine (5 mg) administered intravenously to five patients after a single dose of PPZ-enanthate i.m.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral PPZ treatment in fourteen patients with addition of biperidine or orphenadine given for 3 weeks in fixed oral doses.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Concomitant antiparkinson therapy with PPZ.
Number of subjects: 26
Study: 6668666

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) 0.5g/m2 orally 4 hours before irradiation
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: RF hyperthermia combined with radiation
Number of subjects: 147
Study: 28464331

Group type: EXPERIMENTAL
Intervention: STN DBS
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: GPi DBS
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both GPi and STN DBS
Number of subjects: 128
Study: 25405562

Group type: EXPERIMENTAL
Intervention: Whole body MTV (Metabolic Tumor Volume)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low MTV (<37.2 mL)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Disease burden outside the abdomen <35%
Number of subjects: 17
Study: 24958585

Group type: EXPERIMENTAL
Intervention: Individualized caregiver-mediated intervention (CMM)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Group caregiver education
Number of subjects: 112
Study: 23193746

Group type: EXPERIMENTAL
Intervention: 3% minoxidil lotion (MNX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined 3% minoxidil and 0.1% finasteride lotion (MFX)
Number of subjects: 40
Study: 20233137

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 69

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 69
Study: 18607268

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum and fructooligosaccharides (synbiotic preparation)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dextrose saline placebo
Number of subjects: 31
Study: 16491681

Group type: EXPERIMENTAL
Intervention: Men tested by a female experimenter
Number of subjects: 64

Group type: COMPARATOR
Intervention: Men tested by a male experimenter
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Women tested by a female experimenter
Number of subjects: 64

Group type: COMPARATOR
Intervention: Women tested by a male experimenter
Number of subjects: 64
Study: 12056770

Group type: EXPERIMENTAL
Intervention: Web-based digital records (50 students)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Traditional orthodontic records (49 students)
Number of subjects: 99
Study: 11220538

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: VDD pacing
Number of subjects: 0
Study: 7720150

Group type: EXPERIMENTAL
Intervention: enflurane 0.3%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: enflurane 0.6%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: enflurane 0.9%
Number of subjects: 40

Group type: COMPARATOR
Intervention: control (fentanyl-nitrous oxide anaesthesia)
Number of subjects: 40
Study: 1922206

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 1.25 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral estradiol 2 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 0.1 mg twice a week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7065386

Group type: EXPERIMENTAL
Intervention: Aluminium-coated polyester foil
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Infusion solutions warmed to body temperature and operation theatre temperature raised to 22-24 degrees C
Number of subjects: 80
Study: 31900273

Group type: EXPERIMENTAL
Intervention: Tai chi exercise (12-week programme, 60 min per session, twice weekly)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Balance and postural control training (12-week programme, 60 min per session, twice weekly)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tai chi exercise
Number of subjects: 66

Group type: COMPARATOR
Intervention: Balance and postural control training
Number of subjects: 66
Study: 30348962

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound (RTUS) guidance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional landmark (CL) technique
Number of subjects: 80
Study: 28135963

Group type: EXPERIMENTAL
Intervention: operation‐unit‐based integrated design
Number of subjects: 42

Group type: COMPARATOR
Intervention: action‐based integrated design
Number of subjects: 42

Group type: COMPARATOR
Intervention: existing separated‐displays design
Number of subjects: 42
Study: 25672925

Group type: EXPERIMENTAL
Intervention: STEMO prehospital stroke concept (IV thrombolysis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study: 24074720

Group type: EXPERIMENTAL
Intervention: Isokinetic training program for quadriceps (n=16), 12 weeks, 3 times per week, at angular velocity 150°/s, concentric mode of contraction, 3 sets/day, 3 min rest between sets.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (n=17), home based physical therapy exercise program without isokinetic.
Number of subjects: 33
Study: 22372774

Group type: EXPERIMENTAL
Intervention: Triple-combination therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide (OM/AML/HCTZ)
Number of subjects: 2112
Study: 19732641

Group type: EXPERIMENTAL
Intervention: Warmed levobupivacaine (20 mL of levobupivacaine 5 mg/mL + 0.005 mg/mL epinephrine at 40 degrees C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Room-temperature levobupivacaine (20 mL of levobupivacaine 5 mg/mL + 0.005 mg/mL epinephrine at 25 degrees C)
Number of subjects: 32
Study: 17263634

Group type: EXPERIMENTAL
Intervention: IDV/r 800/100 mg bid
Number of subjects: 70
Study: 15106814

Group type: COMPARATOR
Intervention: Trandolapril 2 mg (T)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Verapamil SR/trandolapril 180/2 mg (V + T)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 438
Study: 11805389

Group type: EXPERIMENTAL
Intervention: Epoetin beta (125 IU/kg, once weekly)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Epoetin beta (250 IU/kg, once weekly)
Number of subjects: 194

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 194
Study: 9746884

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (20 million KIU given over 30 h)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 48
Study: 7872041

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 144

Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both Remoxipride and Thioridazine
Number of subjects: 144
Study: 3258815

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid tablets 300 mg twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid sustained action (SA) capsules 600 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: indomethacin sustained release (SR) capsules 75 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid SA capsules
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: indomethacin SR capsules
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid tablets
Number of subjects: 30
Study: 31599035

Group type: EXPERIMENTAL
Intervention: Numerosity training (apple-collecting game)
Number of subjects: 80

Group type: COMPARATOR
Intervention: English dictation task (control group)
Number of subjects: 80
Study: 31554422

Group type: EXPERIMENTAL
Intervention: Complete angiographically guided revascularization
Number of subjects: 306

Group type: COMPARATOR
Intervention: Stress echocardiography-guided revascularization
Number of subjects: 306
Study: 27600363

Group type: EXPERIMENTAL
Intervention: Acute naltrexone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25841041

Group type: EXPERIMENTAL
Intervention: Amisulpride 38.3 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Aripiprazole 1.4 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Asenapine 0.9 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Chlorpromazine 38.9 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Clozapine 30.6 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Haloperidol 0.7 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Quetiapine 32.3 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Risperidone 0.4 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Sertindole 1.1 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Ziprasidone 7.9 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Zotepine 13.2 mg/d
Number of subjects: 16555

Group type: EXPERIMENTAL
Intervention: Iloperidone, Lurasidone, Paliperidone
Number of subjects: 16555
Study: 24067385

Group type: EXPERIMENTAL
Intervention: Subcutaneous white adipose tissue (SWAT) biopsies pre-intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subcutaneous white adipose tissue (SWAT) biopsies post-intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Energy restriction and weight loss
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 20
Study: 21957703

Group type: EXPERIMENTAL
Intervention: Self-control group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Yoked group
Number of subjects: 30
Study: 19226352

Group type: EXPERIMENTAL
Intervention: Dairy intervention group (IG: n = 39) receiving approximately 1200 mg of calcium and 7.5 microg of vitamin D(3) per day via fortified dairy products and attending biweekly nutrition counselling sessions
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (CG: n = 36)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Calcium-supplemented group (SG: n = 26) receiving a total of 1200 mg calcium per day
Number of subjects: 101
Study: 16420280

Group type: EXPERIMENTAL
Intervention: i.v. aldosterone (100 microg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15087583

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) criteria based on functional and neuropsychological performances
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neuropsychological measures including Letter Cancellation Test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Age and size of temporal lobe
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gender, education, apolipoprotein E4 genotype
Number of subjects: 90
Study: 11168457

Group type: EXPERIMENTAL
Intervention: Protectamin (45 g daily for 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immunocal (45 g daily for 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Protectamin (PMA-induced O2- release)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immunocal (Spontaneous O2- release)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Protectamin and Immunocal (Plasma concentrations of TNF-alpha and interleukins 2 and 12)
Number of subjects: 30
Study: 9355889

Group type: EXPERIMENTAL
Intervention: Dietary intervention (specifics not provided)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 663
Study: 8222489

Group type: COMPARATOR
Intervention: 200 mg cefdinir alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg cefdinir with two tablets of iron ion concomitantly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg cefdinir with two tablets of iron ion preparation 3 hours later
Number of subjects: 0
Study: 3978009

Group type: EXPERIMENTAL
Intervention: Buprenorphine 4.5‐12 micrograms kg‐1 at induction
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Age of the patient
Number of subjects: 51

Group type: COMPARATOR
Intervention: Weight-related dose of buprenorphine, age, sex, body weight, duration of anaesthesia, dose of droperidol or thiopentone
Number of subjects: 51
Study: 30853329

Group type: EXPERIMENTAL
Intervention: Vibration and cold gel pack application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard procedures (Control)
Number of subjects: 0
Study: 28027074

Group type: EXPERIMENTAL
Intervention: Postdischarge patient-centred intervention
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 164
Study: 25820842

Group type: EXPERIMENTAL
Intervention: Ayahuasca (a psychedelic preparation containing N,N-dimethyltryptamine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23504864

Group type: EXPERIMENTAL
Intervention: Dapoxetine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 59
Study: 21172601

Group type: EXPERIMENTAL
Intervention: Extension of the CONSORT statement
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Statistically significant results for efficacy, private funding, primary harms outcome, and anti-infective, antineoplasmatic, or immunosuppressive agents
Number of subjects: 228
Study: 19278589

Group type: EXPERIMENTAL
Intervention: VEGF levels in survivors
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: VEGF levels in patients who died
Number of subjects: 29

Group type: COMPARATOR
Intervention: VEGF levels in healthy control group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Correlation of VEGF levels with APACHE II score
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Correlation of VEGF levels with PLT
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Correlation of VEGF levels with Alb levels
Number of subjects: 29
Study: 17518106

Group type: EXPERIMENTAL
Intervention: Judgments of perceived masculinity or femininity by 10 listeners
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Acoustic measures of talker's speech
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Regression analyses of acoustic measures
Number of subjects: 44
Study: 15030978

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11795467

Group type: EXPERIMENTAL
Intervention: Whole body hyperthermia (39 degrees C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heat treatment of whole blood in vitro for 2 hours at different temperatures (up to 41 degrees C)
Number of subjects: 0
Study: 7846203

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg IV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3073462

Group type: EXPERIMENTAL
Intervention: RU 41740
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30051155

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Attention Control Condition (CC)
Number of subjects: 31
Study: 28342090

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard patch
Number of subjects: 213
Study: 25277390

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (210 IU and 420 IU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous infusion of ins‐asp (0.12 IU/kg/24 h)
Number of subjects: 20
Study: 23620931

Group type: EXPERIMENTAL
Intervention: Balance needling therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21148517

Group type: EXPERIMENTAL
Intervention: Telavancin (10 mg/kg every 24 h)
Number of subjects: 1503

Group type: COMPARATOR
Intervention: Vancomycin (1 g every 12 h)
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 1503

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1503
Study: 18093662

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 300-800 mg/daily (mean final dose 461.6 mg/day)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 16570004

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 12898007

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg orally twice daily for 4 days
Number of subjects: 10
Study: 10725065

Group type: EXPERIMENTAL
Intervention: Neoral (microemulsion formulation of cyclosporin A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sandimmun (original formulation of cyclosporin A)
Number of subjects: 0
Study: 9407976

Group type: EXPERIMENTAL
Intervention: 6-cm J-pouch
Number of subjects: 59

Group type: COMPARATOR
Intervention: 10-cm J-pouch
Number of subjects: 59
Study: 7965224

Group type: EXPERIMENTAL
Intervention: Enriched TPN (53% BCAA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard TPN (30% BCAA)
Number of subjects: 10
Study: 2438997

Group type: EXPERIMENTAL
Intervention: Novel oral rehydration mixture based on fruit juice cordial
Number of subjects: 0